Iatrogenic Creutzfeldt-Jakob Disease (iCJD) is a rare form of CJD transmitted through accidental exposure to prion-contaminated biological materials or medical devices. It represents the first demonstrated example of医源性 (iatrogenic) transmission of a prion disease in humans and has significantly influenced medical safety protocols for tissue banking, surgery, and blood product handling. iCJD accounts for approximately 1-2% of all CJD cases worldwide.
The first recognized cases of iCJD were reported in 1974, resulting from corneal transplantation from an infected donor [1]. Subsequently, additional cases have been linked to:
- Dura mater grafts (1970s-1980s): Largest single source of iCJD
- Human growth hormone (1959-1985): Contaminated pituitary extracts
- Human pituitary gonadotropin (1960s-1970s)
- Blood products (rare, debated)
- Neurosurgical instruments (extremely rare)
The recognition of iCJD has led to:
- Stringent decontamination protocols for surgical instruments
- Donor screening policies for tissue and organ transplantation
- Blood donor deferral policies
- Development of prion-resistant medical devices [2]
| Exposure Type | Reported Cases | Risk Level |
|--------------|----------------|-----------|
| Dura mater graft | ~200+ | Highest | [^6]
| Human growth hormone | ~229 | High | [^7]
| Corneal transplant | 3 | Low | [^8]
| Neurosurgery | 4 | Very low | [^9]
| Blood transfusion | 5 (possible) | Very low |
- Japan: Highest number (dura mater grafts)
- France: Second highest
- United States: Significant number
- United Kingdom: Cases linked to growth hormone
- Other countries: Sporadic cases
Incubation periods vary significantly by exposure type:
- Dura mater graft: 1.5-25 years (median ~12 years)
- Human growth hormone: 5-30 years (median ~12 years)
- Corneal transplant: 1.5-5 years
- Neurosurgery: 1-7 years
- Blood transfusion: 5-8 years (possible cases)
- Growth hormone cases: Mean age ~32 years (younger at exposure)
- Dura mater cases: Mean age ~55 years
- Overall: Variable, depends on exposure age [3]
- Direct CNS exposure: Dura mater grafts, corneal transplants, neurosurgery
- Peripheral exposure: Growth hormone injections, blood products
- Neuroinvasion: Prions transported to CNS via peripheral nerves
- Higher inoculum → shorter incubation period
- Direct CNS exposure → shorter incubation than peripheral
- Species barrier → affects transmission efficiency
iCJD shows similar neuropathological features to sporadic CJD:
- Spongiform change: Vacuolation of neuropil
- Neuronal loss: Progressive neuronal degeneration
- Prion deposition: PrP^Sc in various patterns
- Astrocytic gliosis: Reactive astrocytes
- Amyloid plaques: Variable, may be absent
- Maintains the strain characteristics of the donor's prion
- Preserves the molecular fingerprint (glycosylation pattern)
- Similar to sporadic CJD in most cases [4]
Cognitive symptoms:
- Progressive cognitive decline
- Memory impairment
- Executive dysfunction
- Dementia (typically rapidly progressive)
Neurological symptoms:
- Ataxia (cerebellar involvement common)
- Myoclonus (often early and prominent)
- Pyramidal signs
- Extrapyramidal signs
- Visual disturbances
- Dysarthria
Psychiatric symptoms:
- Depression
- Anxiety
- Behavioral changes
- Psychosis (less common)
- Growth hormone cases: Often present with cerebellar ataxia early
- Dura mater cases: Variable presentation, often typical CJD
- Blood transmission: Variable, limited cases
- Rapid decline: Typically faster than sporadic CJD
- Myoclonus: Often early and prominent
- Akinetic mutism: Common in late stages
- Survival: Usually 4-12 months from symptom onset [5]
Possible iCJD:
- Progressive dementia
- Plus at least two of: myoclonus, visual/cerebellar symptoms, pyramidal/extrapyramidal signs
- History of recognized iatrogenic exposure
Probable iCJD:
- Above clinical criteria
- Plus characteristic EEG (periodic sharp wave complexes)
- Plus characteristic MRI findings
Definite iCJD:
- Neuropathological confirmation
- OR positive prion detection plus documented exposure
Neuroimaging:
- MRI brain: Cortical ribboning, basal ganglia hyperintensity
- Diffusion-weighted imaging: Restricted diffusion
- May be indistinguishable from sporadic CJD
EEG:
- Periodic sharp wave complexes in ~60% of cases
- May be absent early in disease
CSF analysis:
- 14-3-3 protein: Positive in most cases
- Total tau: Elevated
- Neuronal markers
Genetic testing:
- PRNP sequencing to exclude familial CJD
- Codon 129 genotyping
Post-mortem:
- Definitive diagnosis
- Neuropathological confirmation
- PrP immunohistochemistry [6]
- Sporadic CJD
- Familial CJD
- Variant CJD
- Other rapidly progressive dementias
- Autoimmune encephalitis
- Paraneoplastic encephalitis
- Viral encephalitis
- Metabolic encephalopathies
¶ Prevention and Safety Measures
Dura mater:
- Lyophilized dura replaced with synthetic alternatives
- Donor screening implemented
- Heat treatment of dura grafts
Growth hormone:
- Recombinant human growth hormone replaced pituitary-derived
- Screening of pituitary donors
Surgical instruments:
- Extended sterilization protocols (1N NaOH, autoclaving)
- Dedicated instrument sets for high-risk procedures
- Single-use instruments where possible
Blood products:
- Donor deferral for CJD risk factors
- Leukodefiltration
- Plasma products: Heat treatment
WHO Guidelines:
- Decontamination: 1N NaOH for 1 hour, or 2% available chlorine
- Autoclaving: 134°C for 18 minutes (prevacuum)
- Single-use preference for high-risk procedures
National Policies:
- Vary by country
- US: FDA guidance on CJD
- EU: Medical device regulations
- Japan: Stringent tissue screening [7]
No disease-modifying treatments are available. Investigational approaches:
- Quinacrine (not effective)
- Pentosan polysulfate (not effective)
- Anti-prion antibodies (experimental)
- Gene therapy approaches (investigational)
Motor symptoms:
- Myoclonus: Clonazepam, valproic acid, levetiracetam
- Ataxia: Physical therapy, assistive devices
- Spasticity: Baclofen, tizanidine
Cognitive symptoms:
- Supportive care
- Environmental modifications
- Caregiver education
Psychiatric symptoms:
- Antidepressants (SSRIs)
- Antipsychotics for behavioral disturbances
General care:
- Nutritional support
- Swallowing assessment
- Pulmonary hygiene
- Pressure ulcer prevention [8]
- Median survival: 4-12 months from symptom onset
- Incubation period: 1-30 years (exposure-dependent)
- Age at onset: Variable (30-70 years)
- Outcome: Uniformly fatal
- Predictors: Age at onset, codon 129 genotype, exposure type
- Mandatory reporting of suspected iCJD
- International surveillance networks
- Investigation of each suspected case
- Tracking of exposure sources
- Estimated risk from blood products: Very low (~1 in 2-3 million)
- Risk from surgical instruments: Extremely low with proper decontamination
- Risk from tissue transplantation: Mitigated by screening
- Long incubation periods may lead to additional cases
- Subclinical carriers possible
- Need for continued vigilance
- Development of sensitive detection methods [9]
Iatrogenic CJD represents a significant chapter in the history of prion disease research, demonstrating that human prion diseases can be transmitted through medical procedures. While rare, iCJD has profoundly influenced medical safety practices and continues to inform policies around tissue banking, surgical instrument decontamination, and blood product safety. The prevention of iCJD through stringent safety protocols remains a model for addressing emerging infectious risks in medicine.
This section highlights recent publications relevant to this disease.